The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Interstitial pneumonitis associated with infliximab therapy in a rheumatoid arthritis patient

류마티스 관절염 환자에서 infliximab 치료 후 발생한 간질성 폐렴 1예

  • Yoo, In-Seol (Department of Internal Medicine, Chungnam National University College of Medicine) ;
  • Song, Ju-Kyoung (Division of Rheumatology, Taejon Choongang General Hospital)
  • 유인설 (충남대학교 의과대학 내과학교실) ;
  • 송주경 (대전중앙병원 류마티스내과)
  • Received : 2009.06.30
  • Accepted : 2009.09.21
  • Published : 2010.08.01
⟨ Previous Next ⟩

Abstract

Tumor necrosis factor (TNF)-${\alpha}$ inhibitors are well-established biological agents for the treatment of a wide variety of chronic autoimmune diseases and inflammatory conditions, including rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Although these drugs have been noted to have good safety profiles, some important side effects, including infection, injection site reactions, lupus-like syndrome, congestive heart failure, and malignancies have been reported. Therefore, utilization of TNF-${\alpha}$ inhibitors demands caution. Interstitial pneumonitis is a very rare complication of TNF-${\alpha}$ inhibitors. We report here a 71-year-old man with RA who developed interstitial pneumonitis after the third infusion of infliximab.

종양괴사인자 억제제는 류마티스 관절염에서 효과 및 안정성이 입증되어 현재 보편화된 치료이다. 부작용으로는 결핵 및 감염에 의한 폐렴, 급성 주사 반응, 루프스 유사 증후군, 악성 종양, 울혈성 심부전의 악화 등이 있으며 드물게 비감염성 간질성 폐렴이 외국에서 보고되었다. 비감염성 간질성 폐렴은 주로 methotrexate와 병용할 때 호발하며 국내에서는 아직 보고된 바가 없다. 저자들은 종양괴사인자 억제제인 infliximab을 사용한 류마티스 관절염 환자에서 발생한 비감염성 간질성 폐렴으로 고용량의 스테로이드를 사용한 후 호전된 증례를 경험하여 보고하는 바이다.

Keywords

References

  1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343:1594-1602, 2000 https://doi.org/10.1056/NEJM200011303432202
  2. Vassallo R, Thomas CF. Advances in the treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 16:186-191, 2004 https://doi.org/10.1097/00002281-200405000-00004
  3. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 59:757-759, 2008 https://doi.org/10.1002/art.23723
  4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354:1932-1939, 1999 https://doi.org/10.1016/S0140-6736(99)05246-0
  5. Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. Mod Rheumatol 16:251-255, 2006 https://doi.org/10.1007/s10165-006-0491-5
  6. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 47:670-671, 2002 https://doi.org/10.1002/art.10803
  7. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 33:1189-1193, 2006
  8. Wiener CM, Muse VV, Mark EJ. A 63-year-old woman with dyspnea on exertion. N Engl J Med 359:1823-1832, 2008 https://doi.org/10.1056/NEJMcpc0806979
  9. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, Kamatani N, Harigai M, Ryu J, Inoue K, Kondo H, Inokuma S, Ochi T, Koike T. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194, 2008 https://doi.org/10.1136/ard.2007.072967
  10. Kuroki M, Noguchi Y, Shimono M, Tomono K, Tashiro T, Obata Y, Nakayama E, Kohno S. Repression of bleomycin-induced pneumopathy by TNF. J Immunol 170:567-574, 2003
  11. Gosset P, Perez T, Lassalle P, Duquesnoy B, Farre JM, Tonnel AB, Capron A. Increased TNF-alpha secretion by alveolar macrophages from patients with rheumatoid arthritis. Am Rev Respir Dis 143:593-597, 1991 https://doi.org/10.1164/ajrccm/143.3.593
  12. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251-259, 1995 https://doi.org/10.1006/cyto.1995.0029
  13. 김지연, 김완욱, 김성일, 류완희, 박성환, 홍연식, 김석찬, 조철수, 김호연, 이연수. 류마티스관절염 환자에서 Methotraxate와 관련된 간질성 폐렴 1예. 대한류마티스학회지 5:126-132, 1998
  14. 지종대, 이영호, 송관규. 류마티스 관절염 환자에서 간질성 폐질환 유무에 대한 임상양상의 비교. 대한류마티스학회지 5:187-192, 1998